Zyoud SH, Smale S, Waring WS, Sweileh W, Al-Jabi SW. Global research trends in the microbiome related to irritable bowel syndrome: A bibliometric and visualized study. World J Gastroenterol 2021; 27(13): 1341-1353 [PMID: 33833487 DOI: 10.3748/wjg.v27.i13.1341]
Corresponding Author of This Article
Sa'ed H Zyoud, PhD, Associate Professor, Director, Poison Control and Drug Information Center (PCDIC), College of Medicine and Health Sciences, An-Najah National University, Academic Street, Nablus 44839, West Bank, Palestine. saedzyoud@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Scientometrics
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zyoud SH, Smale S, Waring WS, Sweileh W, Al-Jabi SW. Global research trends in the microbiome related to irritable bowel syndrome: A bibliometric and visualized study. World J Gastroenterol 2021; 27(13): 1341-1353 [PMID: 33833487 DOI: 10.3748/wjg.v27.i13.1341]
World J Gastroenterol. Apr 7, 2021; 27(13): 1341-1353 Published online Apr 7, 2021. doi: 10.3748/wjg.v27.i13.1341
Global research trends in the microbiome related to irritable bowel syndrome: A bibliometric and visualized study
Sa'ed H Zyoud, Simon Smale, W Stephen Waring, Waleed Sweileh, Samah W Al-Jabi
Sa'ed H Zyoud, Poison Control and Drug Information Center (PCDIC), College of Medicine and Health Sciences, An-Najah National University, Nablus 44839, West Bank, Palestine
Sa'ed H Zyoud, Samah W Al-Jabi, Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus 44839, West Bank, Palestine
Sa'ed H Zyoud, Department of Clinical Research Centre, An-Najah National University Hospital, Nablus 44839, West Bank, Palestine
Simon Smale, Department of Gastroenterology, York Hospital, York Teaching Hospital NHS Foundation Trust, York YO31 8HE, United Kingdom
W Stephen Waring, Acute Medical Unit, York Teaching Hospitals NHS Foundation Trust, York YO31 8HE, United Kingdom
Waleed Sweileh, Department of Pharmacology and Toxicology, College of Medicine and Health Sciences, An-Najah National University, Nablus 44839, West Bank, Palestine
Author contributions: Zyoud SH designed the study, collected the data, analyzed the data, made major contributions to the manuscript’s existing literature search and interpretation, and drafted the manuscript; Al-Jabi SW, and Sweileh W participated in the study design; Smale S and Waring WS contributed towards the conception, wrote part of the article; Al-Jabi SW, Sweileh W, Smale S and Waring WS were involved in interpretation of the data, and made revisions to the initial draft; all authors provided critical review and approved the final manuscript before submission.
Conflict-of-interest statement: The authors have no financial disclosures or conflicts of interest to declare.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Sa'ed H Zyoud, PhD, Associate Professor, Director, Poison Control and Drug Information Center (PCDIC), College of Medicine and Health Sciences, An-Najah National University, Academic Street, Nablus 44839, West Bank, Palestine. saedzyoud@yahoo.com
Received: November 18, 2020 Peer-review started: November 18, 2020 First decision: December 27, 2020 Revised: January 11, 2021 Accepted: March 16, 2021 Article in press: March 16, 2021 Published online: April 7, 2021 Processing time: 132 Days and 2.9 Hours
ARTICLE HIGHLIGHTS
Research background
The ability of specific bacteria to boost the development and the effects of proinflammatory cytokines can result in low-grade inflammation seen in a proportion of patients with irritable bowel syndrome (IBS).
Research motivation
The current bibliometric analysis plays an important role for researchers interested in the relationship between the microbiome and IBS. It provides a simple reference guide for interdisciplinary researchers to learn how scientific experts have examined this area in previous years.
Research objectives
This study aimed to carry out a bibliometric review of the IBS and the microbiome literature to explain the growth of this field and assist the identification of unique focus areas that may be important for future research.
Research methods
The information used in our bibliometric research was derived from the Scopus database. Terms related to IBS and the microbiome were searched in titles or abstracts during the period of 2000–2019. For data visualization, VOSviewer software was used.
Research results
Since 2013, the number of publications on gut microbiota in IBS has continuously increased. This result indicates that the future outlook remains optimistic for treatments targeting the gut microbiota in IBS.
Research conclusions
This is the first study to analyze and measure the global research productivity of IBS and microbiome research to provide a holistic view of this evolving subject and explore future research directions. It is evident that, due to the growing understanding of the role of the gut microbiota, research productivity in this area has steadily increased. Currently, the key hot topics are the gut–brain axis related to IBS, clinical trials related to IBS and the microbiome, drug-mediated modulation of the gut microbiome, and the role of the altered composition of the intestinal microbiome in the prevention of IBS.
Research perspectives
Our results indicate that the future outlook for IBS therapies targeting the intestinal microbiota remains promising.
